Daily Archives: March 28, 2022
An Unusual Case of Gallbladder Emergency
Posted in News
Comments Off on An Unusual Case of Gallbladder Emergency
One step forward, two steps back? Disproportionate loss of scientific productivity with long-term effects among women and caregivers during the pandemic
Posted in News
Comments Off on One step forward, two steps back? Disproportionate loss of scientific productivity with long-term effects among women and caregivers during the pandemic
Targeting IRAK4 signaling in PDAC: Turning the ‘cold’ tumors to ‘hot’ ones.
Posted in News
Comments Off on Targeting IRAK4 signaling in PDAC: Turning the ‘cold’ tumors to ‘hot’ ones.
HIF-2 in cancer associated fibroblasts polarizes macrophages and creates an immunosuppressive tumor microenvironment in pancreatic cancer
Posted in News
Comments Off on HIF-2 in cancer associated fibroblasts polarizes macrophages and creates an immunosuppressive tumor microenvironment in pancreatic cancer
Endoscopic Screening Program for Control of Esophageal Adenocarcinoma in Varied Populations: A Comparative Cost-Effectiveness Analysis
Guidelines suggest endoscopic screening for esophageal adenocarcinoma (EAC) among individuals with symptoms of gastroesophageal reflux disease (GERD) and additional risk factors. We aimed to determine at what age to perform screening and whether sex an… Continue reading
Posted in News
Comments Off on Endoscopic Screening Program for Control of Esophageal Adenocarcinoma in Varied Populations: A Comparative Cost-Effectiveness Analysis
Effect of Helicobacter pylori Eradication on Gastric Cancer Prevention: Updated Report from a Randomized Controlled Trial with 26.5 Years of Follow-up
Helicobacter pylori (H. pylori) infection is considered as the most important risk factor in the pathogenesis of gastric cancer. This study aims to evaluate the long-term effects of H. pylori eradication treatment on the incidence and mortality of gast… Continue reading
Posted in News
Comments Off on Effect of Helicobacter pylori Eradication on Gastric Cancer Prevention: Updated Report from a Randomized Controlled Trial with 26.5 Years of Follow-up
Has the Time Come to Say Goodbye to Therapeutic Drug Monitoring As We Know It?
The need for the SERENE studies of high-dose adalimumab induction therapy was clear. From the first randomized controlled trial evaluating the efficacy and safety of adalimumab for the management Crohn’s disease, CLASSIC-I trial, we were confident abou… Continue reading
Posted in News
Comments Off on Has the Time Come to Say Goodbye to Therapeutic Drug Monitoring As We Know It?